Parenteral Drugs (India) Limited(BSE:524689 NSE:PDPL) ,Company Snapshot, Recent Developments, Latest News, Financials, Price Charts, Ratios, Contact Information

Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals

Home

News Centre

IPO

Markets	Companies	Research	Industries	E-Mail Page

my Last 5 Scrips
Company	BSE Price(Rs)	% Chg
I T C Lt	334.70	0.62
Bhel	201.35	4.00
Tata Mot	303.35	0.05
Hindalco	110.15	0.90
Tata Stl	311.95	10.83
Clear All	Clear Last

NSE Live
Nifty Live Prices Live Quotes Top Gainers/Losers Top 10 Turnover No Delivery Stocks

BSE Live
BSE30 Live Prices Live Quotes Top Gainers/Losers Top 10 Turnover No Delivery Stocks

Market Pulse
Leaders Laggards FII Activity Mutual Fund Activity Meetings

Results Watch
Results Calendar Results Announced

IPO Watch

Company
Snapshots Quotes Charts Financials Recent News Broker Research Meetings Research Tutorial Discussion Forum

Research
Research Reports

Sector Watch

Economy Watch

Snapshot-Parenteral Drugs (India) Limited

Parenteral Drugs (India) Limited

Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:524689	NSE:PDPL	Bloomberg:PDI@IN	Reuters:PADG.BO
Market Lot: 1	Face Value: 10	ISIN Demat: INE904D01019

Quotes	Snapshot	Charts	Financials	Research	Recent News
Peer Group	AGM/AM	MF Holding	Discussion Forum	BSE/NSE Notices	BSE/NSE Deals

Recent Developments
11-NOV-10 The company has posted a 125.62% or 2.25 times rise net profit at Rs 202 million for the second-quarter ended Sep.30, 2010 compared to Rs 89.5 million in the corresponding quarter ended Sep. 30, 2009. 15-SEP-10 Parenteral Drugs (India) today announced that it has issues and allotted bonus shares in the ratio of 1:3 i.e 1 fully paid up bonus share for every 3 fully paid up equity shares held by the members of the company. 02-SEP-10 ... More..
Business Profile	Future Plans

One To One

Latest News

Parenteral Drugs arm sells manufacturing unit to Fresenius Kabi -IRIS 15-Mar-13

Brief Financials (in Rs. Mn.)

Period ending (months)	31-Dec-2012(9)	31-Mar-2012 (12)	31-Mar-2011 (12)
Net sales	1353.47	2225.61	3966.52
Other Income	0.00	0.00	0.00
Total Income	1353.47	2225.61	3966.52
Cost of goods sold	1533.88	2140.05	3524.49
OPBDIT	-180.41	85.56	442.03
PAT	-672.80	-478.16	88.64
Gross Block	-	-	-
Equity capital	258.67	258.67	258.67
EPS (Rs.)	-	-18.49	3.43
DPS (Rs.)	-	-	-
BV (Rs.)	-	-	-
P/E range (x)	-	NA	39.11 - 116.60
Debt / Equity (x)	-	-	-
Operating margin (% of OI)	-13.3	3.8	11.1
Net margin (% of OI)	-49.7	-21.5	2.2